- Third-party tested
- >99% purity
- 99%+ purity or full refund
- Same-day shipping

CJC-1295 (no DAC) + Ipamorelin Blend
CJC-1295 (no DAC) + Ipamorelin — GHRH analog and ghrelin-receptor agonist synergy blend
Verify this batch
- Same-day shipping before 12pm
- Free US shipping over $100
- 99%+ purity or full refund
- Secure checkout
This blend combines CJC-1295 (modified GRF 1-29, no DAC) — a short-acting GHRH analog with a half-life of approximately 30 minutes — with Ipamorelin, a selective ghrelin-receptor agonist (growth hormone secretagogue). The two molecules act on parallel but distinct receptors of the somatotropic axis: CJC-1295 amplifies the GHRH signal, while Ipamorelin mimics ghrelin to trigger GH release without significantly elevating cortisol, prolactin, or ACTH. The 'no DAC' designation indicates the molecule lacks the Drug Affinity Complex, preserving the natural pulsatile GH-release pattern that is critical in many research designs.
Key research areas
Studied for its ability to produce a clean, pulsatile growth-hormone response in animal models — mimicking physiological release patterns.
Investigated for downstream IGF-1 elevation and the kinetics of the GH/IGF-1 feedback loop.
Preclinical research examines effects on lean mass accrual and adipose tissue distribution.
Animal studies explore the impact of pulsatile GH release on slow-wave sleep duration and quality.
- CAS number
- 863288-34-0 (CJC-1295) / 170851-70-4 (Ipamorelin)
- Molecular formula
- C152H252N44O42 (CJC-1295) · C38H49N9O5 (Ipamorelin)
- Molecular weight
- 3367.94 / 711.85
- Purity
- ≥99.0% each component
- PubChem ID
- 16137769
GH pulsatility
Studied for its ability to produce a clean, pulsatile growth-hormone response in animal models — mimicking physiological release patterns.
IGF-1 dynamics
Investigated for downstream IGF-1 elevation and the kinetics of the GH/IGF-1 feedback loop.
Lean mass & body composition
Preclinical research examines effects on lean mass accrual and adipose tissue distribution.
Sleep architecture
Animal studies explore the impact of pulsatile GH release on slow-wave sleep duration and quality.
- Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
- Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561.
- Sinha DK et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149-S159.
Store lyophilized peptide at −20°C, protected from light and moisture. Once reconstituted, store at 2–8°C and use within 30 days.
Specifications
- CAS
- 863288-34-0 (CJC-1295) / 170851-70-4 (Ipamorelin)
- Formula
- C152H252N44O42 (CJC-1295) · C38H49N9O5 (Ipamorelin)
- MW
- 3367.94 / 711.85
- Purity
- ≥99.0% each component
Our process
Lyophilization
Each peptide is freeze-dried under controlled vacuum conditions, ensuring long-term stability and consistent potency across every vial.
Verified purity
Every batch is tested by independent third-party labs using HPLC and mass spectrometry. Certificates of analysis are published for each product.
Same-day fulfillment
Orders placed before 12pm ship the same business day. We use insulated packaging and cold packs where required.
Frequently asked questions
Each vial contains lyophilized peptide powder at the labeled dosage. No solvents, fillers, or preservatives.
Every batch is HPLC-tested. Certificate of Analysis (COA) and HPLC report are available on the product page.
Store the lyophilized peptide at −20°C, dry and dark. See the Storage tab for product-specific details.
United States only, in temperature-controlled packaging. 3–5 day standard or 1–2 day express.
No. All products are for laboratory and research use only (RUO) and are not intended for human or veterinary use.


